Medical Condition News

RSS

ESMO-symposium to highlight recent advancement in cancer biology

This ESMO-symposium will allow bed-side oriented oncologists to grasp key and timely-issues related to cancer biology. All presentations will have a clear focus towards potential clinical implications thus helping clinicians fully comprehend the major consequences that new developments in cancer biology may have in daily care.

12 Nov 2010

Diabetic drug may retard growth of fluid-filled cysts in PKD: Research

Researchers report that a drug commonly used to treat diabetes may also retard the growth of fluid-filled cysts of the most common genetic disorder, polycystic kidney disease.

12 Nov 2010

New catheter device for abdominal aortic aneurysm

William E. Sorfleet had a life-threatening abdominal aortic aneurysm, but at age 82, he was too old for major invasive surgery to repair the bulging blood vessel. So vascular surgeon Dr. Ross Milner of Loyola University Hospital repaired the aneurysm with a catheter device instead of a scalpel. The catheter, inserted through an artery, deployed a device called a stent graft that repaired the aneurysm.

12 Nov 2010

33rd CTRC-AACR Symposium to feature breast cancer research

The 33rd CTRC-AACR San Antonio Breast Cancer Symposium will feature the latest findings in prevention, epidemiological, laboratory, translational and clinical breast cancer research. This year's symposium will highlight new therapies in the pipeline, new approaches with existing agents and emerging biology that will affect the quest for personalized medicine.

12 Nov 2010

COMP issues positive opinion for Celsion's ThermoDox Orphan Drug Designation

Celsion Corporation, a leading oncology drug development company, today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion on the application for Orphan Drug Designation for ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, for the treatment of hepatocellular carcinoma (HCC), commonly referred to as primary liver cancer.

12 Nov 2010

NaturalNano's HNT can improve separation of CTCs from blood

NaturalNano, Inc. announced that Andrew Hughes is presenting today research from Cornell University's Department of Biomedical Engineering that reports significant improvement in the ability of medical devices in development to target the separation of circulating tumor cells (CTCs) from blood are significantly improved by the use of NaturalNano's Halloysite Nanotubes (HNT) as part of the surface. The devices are designed to remove CTCs from the blood of cancer patients as part of a more personalized approach to cancer treatment.

12 Nov 2010

Acetylon receives two grants under QTDP program to advance HDAC6 inhibitor drug candidate

Acetylon Pharmaceuticals, Inc. today announced that it has been awarded two grants totaling $488,000 under the Qualifying Therapeutic Discovery Project (QTDP) program.

12 Nov 2010

Bristol-Myers Squibb announces first large-scale diabetes initiative to develop self-management program

The Bristol-Myers Squibb Foundation today announced Together on Diabetes: Communities Uniting to Meet America's Diabetes Challenge, a 5-year, $100 million initiative to help patients living with type 2 diabetes better manage their disease beyond the doors of their doctor's office in their homes and communities and for the course of their disease.

12 Nov 2010

Advaxis receives $244,479 QTDP credit for ADXS11-001 trial

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company was awarded a Qualifying Therapeutic Discovery Project (QTDP) credit from the Federal Government for ADXS11-001, the Company's lead immunotherapeutic construct totaling $244,479.

12 Nov 2010

Study finds arsenic improves survival rate in APL patients

Arsenic, a toxic compound with a reputation as a good tool for committing homicide, has a significant positive effect on the survival of patients with acute promyelocytic leukemia (APL), when administered after standard initial treatment, according to a new, multi-center study led by a researcher at Wake Forest University Baptist Medical Center.

12 Nov 2010

SCYNEXIS receives four grants under QTDP program to develop cyclophilin inhibitors

Drug discovery and development company SCYNEXIS, Inc. today announced that the Company has been awarded four grants totaling $977,917 under the U.S. Federal Government's Qualifying Therapeutic Discovery Project (QTDP). SCYNEXIS is developing a proprietary internal pipeline of cyclophilin inhibitors, a class of drugs that hold significant potential for the treatment of a broad range of diseases.

11 Nov 2010

StemCyte receives two cash grants under QTDP program for biomedical research

StemCyte, Inc., one of the world's preeminent umbilical cord blood (UCB) banks and biotherapy companies, is proud to announce that the Company has been awarded two cash grants totaling $488,950 under the U.S. Internal Revenue Service's Qualifying Therapeutic Discovery Project (QTDP) program designed to support biomedical research by firms with fewer than 250 employees.

11 Nov 2010

NCI awards $11.5 million to Fred Hutchinson Center for breast cancer research

The National Cancer Institute has awarded $11.5 million to Fred Hutchinson Cancer Research Center to lead a five-year, Seattle-based breast cancer research consortium. The goal of the endeavor is to positively impact breast cancer prevention, detection, treatment and care of women who have or are at risk for the disease.

11 Nov 2010

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

NephRx Corporation today announced that it has initiated a Phase I clinical trial of its lead compound NX001 and has successfully dosed the first subject in the study. NX001, a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure, is in development for the prevention of delayed graft function (DGF) in kidney transplantation patients.

11 Nov 2010

Women abused as kids at increased risk of developing diabetes: Study

The latest research shows that women who were victims of childhood abuse may be at increased risk of developing diabetes in adulthood. For the study the scientist team looked at 67,853 U.S. nurses in the Nurses Health Study II and found that 54 percent reported physical abuse and 34 percent reported sexual abuse before age 18. Moderate and severe physical and sexual abuse was associated with a 26 percent to 69 percent increased risk of type 2 diabetes in adulthood.

11 Nov 2010

Howza launches 'I choose to live' music video to increase awareness of impact of diabetes

Howza (Tshepo Mosese), South African Kwaito star, presenter and actor, has launched a music video for his latest song "I choose to live" on November 10 in an effort to increase awareness of the impact of Diabetes in the world. Inspired by Howza's own story of living with diabetes the song describes the distressing impact diabetes is having on the world and the importance of prevention. Written and performed with fellow South African artist Omen, the song features the voices of the celebrated Soweto Gospel Choir, who lost a member to diabetes seven years ago.

11 Nov 2010

New website helps people to endure difficult situations through inspirational stories

A new inspirational stories website, 'GotInspiration.org,' is connecting those who have endured some of life's most difficult situations with those who are looking for inspiration. From quitting drinking to managing post traumatic stress disorder, to surviving cancer, GotInspiration.org is helping people find inspiration and strength, one true story at a time.

11 Nov 2010

New model of care for rural-dwelling adults

A novel project set in a rural community near Rochester, N.Y., to screen elderly people for unmet needs showed that, indeed, there is a great opportunity to match older adults with professional assistance. This new model of care for rural-dwelling adults is described this month in the Journal of the American Geriatrics Society.

11 Nov 2010

Hospital for Special Surgery presents advantages of specialized disease center for comprehensive lupus care

The benefits of collaborative, multidisciplinary care of patients with complex autoimmune diseases like lupus and multiple sclerosis are just beginning to be appreciated by physicians. Hospital for Special Surgery in New York will present evidence of the advantages of such a specialized disease center dedicated to comprehensive lupus care at the 74th Annual Meeting of the American College of Rheumatology in Atlanta.

11 Nov 2010

Number of smokers quitting has fallen since recession hit the UK economy

Since the recession began the number of smokers quitting has fallen according to new research being presented at the NCRI Cancer Conference in Liverpool today.

11 Nov 2010